Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...

Semaglutide's FDA approval for preventing heart ... showing efficacy in diverse patient subgroups. High serum vitamin B12 concentrations correlate with increased all-cause mortality risk ...

Detailed results from Novo's trial testing the higher dose of Wegovy, which contains the active ingredient semaglutide, are expected to be presented at a scientific conference in 2025, according ...

Novo’s booming semaglutide franchise for diabetes and obesity is the standout inclusion in this year’s list. The U.S. Department of Health and Human Services unveiled the list of 15 drugs Friday.

Wegovy (semaglutide) is a prescription drug used for weight management and heart disease related to obesity. Wegovy can cause side effects that range from mild to serious. Examples include ...

Ozempic is an FDA-approved medication for treating type 2 diabetes. Its active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that acts like the GLP-1 hormone ...

It seemed simple enough: She was charged a subscription fee and a fee for the medication she ordered, semaglutide, which is basically generic Ozempic. She quickly noticed her food cravings and ...

Semaglutide, developed by Novo Nordisk and marketed under brand names such as Ozempic® and Wegovy®, has revolutionized treatment for Type 2 diabetes and obesity. By mimicking glucagon-like ...

Single injection of ProLynx long-acting semaglutide produced 20% weight loss in diet-induced obese mice, which is comparable to multiple semaglutide injections over the same period The paper ...